Yongzhao Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yongzhao Zhou has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
- Ting Niu
Department of Hematology, Institute of Hematology West China Hospital, Sichuan University Chengdu China
5 shared publications Meng Li
Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Chengdu, China
4 shared publicationsXinai Gan
Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Chengdu, China
4 shared publications- Yuhui Chen
Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Chengdu, China
3 shared publications Anjiao Peng
Department of Neurology West China Hospital Sichuan University No. 37 Guo Xue Xiang 610041 Chengdu Sichuan China
2 shared publications- Lei Chen
Department of Neurology, West China Hospital, Sichuan University, Chengdu, China
2 shared publications
Latest Publications
- Open Access
- 13 July 2026
- Published by Springer Nature in BMC Microbiology
- Vol. 26 (1)
Blood mNGS: an effective non-invasive diagnostic tool for Pneumocystis jirovecii pneumonia
Pneumocystis jirovecii pneumonia (PJP) is a life-threatening opportunistic infection. Colonization is prevalent but cannot be reliably distinguished from a
- 13 July 2026
- Published by Springer Nature in BMC Microbiology
- Vol. 26 (1)
Open AccessBlood mNGS: an effective non-invasive diagnostic tool for Pneumocystis jirovecii pneumonia
Pneumocystis jirovecii pneumonia (PJP) is a life-threatening opportunistic infection. Colonization is prevalent but cannot be reliably distinguished from a
- Open Access
- 2 June 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (6) , e0338425
The diagnostic and prognostic utility of blood metagenomic next-generation sequencing for invasive pulmonary aspergillosis
Differentiating invasive pulmonary aspergillosis (IPA) from colonization in patients with Aspergillus -positive blood metagenomic next-generation sequencing (mNGS) remains a clinical challenge. This study aims to evaluate the diagnostic and prognostic value of blood mNGS-derived fungal load (reads per million [RPM]) and two key serological biomarkers (galactomannan [GM] and 1,3-β-D-glucan [BDG]) in distinguishing these two entities. This retrospective study enrolled 95 patients with Aspergillus detected by blood mNGS, stratified into infection ( n = 60) and colonization ( n = 35) groups using modified EORTC/MSGERC criteria. We analyzed clinical characteristics, co-infection spectra, and serological biomarkers (GM and BDG). Diagnostic performance was evaluated via receiver operating characteristic (ROC) analysis, and prognostic factors for 28-day mortality were identified using least absolute shrinkage and selection operator-Cox regression. Distinct co-infection patterns were observed between groups: the infection group was dominated by polymicrobial co-infections, including clinically significant pathogens such as Acinetobacter baumannii , Klebsiella pneumoniae , Mucor spp., and Human cytomegalovirus ; in contrast, the colonization group primarily featured single viral co-infections. While mNGS effectively detected Aspergillus , RPM alone showed limited ability to discriminate infection from colonization, with area under the curves (AUCs) ranging from 0.406 to 0.657 across patient groups. The optimal RPM cutoff varied substantially by immune status, being highest in immunocompetent patients (RPM cutoff: 1.77). Diagnostic performance significantly improved when RPM was integrated with GM (AUC up to 0.900 at a cutoff of 0.36 optical density index) or BDG (AUC up to 0.881 pg/mL), particularly in immunocompetent individuals. RPM also correlated with albumin, hemoglobin, platelet counts, and lymphocyte counts (all P < 0.05). Multivariate analysis identified reversed halo sign (hazard ratio [HR] = 2.143), decreased ratio of partial pressure of arterial oxygen to fraction of inspired oxygen (PaO 2 /FiO 2 ; HR = 1.361), and elevated lactate dehydrogenase (HR = 1.055) as independent predictors of 28-day mortality. Blood mNGS demonstrates high sensitivity for detecting Aspergillus but requires integration with serological biomarkers to differentiate IPA from colonization. The RPM can offer prognostic utility. A multimodal strategy is crucial for early diagnosis and improving outcomes in high-risk patients. IMPORTANCE: First large-scale validation of blood mNGS for invasive pulmonary aspergillosis diagnosis—this study represents the first sizable cohort systematically evaluating blood metagenomic next-generation sequencing (mNGS) for distinguishing invasive pulmonary aspergillosis from colonization, addressing a critical gap in non-invasive diagnostic approaches for critically ill patients. Comprehensive Aspergillus co-infection profiling—we identified distinct co-infection patterns, with the infection group showing significantly higher rates of polymicrobial infections, providing crucial insights into co-infection dynamics in Aspergillosis . Optimized diagnostic integration strategy—our findings demonstrate that while mNGS-derived reads per million alone show limited diagnostic value, their integration with serological biomarkers significantly improves performance, establishing a clinically relevant multimodal diagnostic framework. Robust prognostic stratification model—through least absolute shrinkage and selection operator-Cox regression, we established a validated prognostic model identifying reversed halo sign, decreased PaO 2 /FiO 2 , and elevated lactate dehydrogenase as independent predictors of 28-day mortality, providing clinically actionable tools for risk stratification.
- 2 June 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (6) , e0338425
Open AccessThe diagnostic and prognostic utility of blood metagenomic next-generation sequencing for invasive pulmonary aspergillosis
Differentiating invasive pulmonary aspergillosis (IPA) from colonization in patients with Aspergillus -positive blood metagenomic next-generation sequencing (mNGS) remains a clinical challenge. This study aims to evaluate the diagnostic and prognostic value of blood mNGS-derived fungal load (reads per million [RPM]) and two key serological biomarkers (galactomannan [GM] and 1,3-β-D-glucan [BDG]) in distinguishing these two entities. This retrospective study enrolled 95 patients with Aspergillus detected by blood mNGS, stratified into infection ( n = 60) and colonization ( n = 35) groups using modified EORTC/MSGERC criteria. We analyzed clinical characteristics, co-infection spectra, and serological biomarkers (GM and BDG). Diagnostic performance was evaluated via receiver operating characteristic (ROC) analysis, and prognostic factors for 28-day mortality were identified using least absolute shrinkage and selection operator-Cox regression. Distinct co-infection patterns were observed between groups: the infection group was dominated by polymicrobial co-infections, including clinically significant pathogens such as Acinetobacter baumannii , Klebsiella pneumoniae , Mucor spp., and Human cytomegalovirus ; in contrast, the colonization group primarily featured single viral co-infections. While mNGS effectively detected Aspergillus , RPM alone showed limited ability to discriminate infection from colonization, with area under the curves (AUCs) ranging from 0.406 to 0.657 across patient groups. The optimal RPM cutoff varied substantially by immune status, being highest in immunocompetent patients (RPM cutoff: 1.77). Diagnostic performance significantly improved when RPM was integrated with GM (AUC up to 0.900 at a cutoff of 0.36 optical density index) or BDG (AUC up to 0.881 pg/mL), particularly in immunocompetent individuals. RPM also correlated with albumin, hemoglobin, platelet counts, and lymphocyte counts (all P < 0.05). Multivariate analysis identified reversed halo sign (hazard ratio [HR] = 2.143), decreased ratio of partial pressure of arterial oxygen to fraction of inspired oxygen (PaO 2 /FiO 2 ; HR = 1.361), and elevated lactate dehydrogenase (HR = 1.055) as independent predictors of 28-day mortality. Blood mNGS demonstrates high sensitivity for detecting Aspergillus but requires integration with serological biomarkers to differentiate IPA from colonization. The RPM can offer prognostic utility. A multimodal strategy is crucial for early diagnosis and improving outcomes in high-risk patients. IMPORTANCE: First large-scale validation of blood mNGS for invasive pulmonary aspergillosis diagnosis—this study represents the first sizable cohort systematically evaluating blood metagenomic next-generation sequencing (mNGS) for distinguishing invasive pulmonary aspergillosis from colonization, addressing a critical gap in non-invasive diagnostic approaches for critically ill patients. Comprehensive Aspergillus co-infection profiling—we identified distinct co-infection patterns, with the infection group showing significantly higher rates of polymicrobial infections, providing crucial insights into co-infection dynamics in Aspergillosis . Optimized diagnostic integration strategy—our findings demonstrate that while mNGS-derived reads per million alone show limited diagnostic value, their integration with serological biomarkers significantly improves performance, establishing a clinically relevant multimodal diagnostic framework. Robust prognostic stratification model—through least absolute shrinkage and selection operator-Cox regression, we established a validated prognostic model identifying reversed halo sign, decreased PaO 2 /FiO 2 , and elevated lactate dehydrogenase as independent predictors of 28-day mortality, providing clinically actionable tools for risk stratification.
- Open Access
- 23 December 2025
- Published by Springer Nature in Virology Journal
- Vol. 22 (1) , 397
Reply to Sheybani et al : Diagnostic criteria for Epstein-Barr virus-associated encephalitis: A comment on Liu et al
- 23 December 2025
- Published by Springer Nature in Virology Journal
- Vol. 22 (1) , 397
Open AccessReply to Sheybani et al : Diagnostic criteria for Epstein-Barr virus-associated encephalitis: A comment on Liu et al
- Open Access
- 1 October 2025
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 18, 5263-5275
Metagenomic Next-Generation Sequencing Unveils Prognostic Microbial Synergism and Guides Precision Therapy in Candidemia: A Retrospective Cohort Study
Purpose: Candidemia remains a life-threatening infection, compounded by diagnostic delays and limited prognostic tools. While metagenomic next-generation sequencing (mNGS) offers rapid pathogen detection, its prognostic utility and therapeutic impact in candidemia remain unestablished. Patients and Methods: This retrospective cohort study analyzed 97 candidemia patients with positive blood mNGS at West China Hospital (2020– 2024). Multivariable logistic regression and survival analyses identified mortality predictors, while therapeutic impacts were assessed through antifungal regimen modifications. Results: The 28-day mortality was 44.3% (43/97). Blood mNGS outperformed cultures in species identification (5 vs 4 species) and co-infection detection. Bacterial co-detections (HR=2.00, 95% CI:1.15– 3.48; p< 0.05) doubled mortality risk. SOFA score was the strongest mortality predictor (adjusted OR=1.29 per point; p< 0.001). mNGS-guided antifungal initiation reduced mortality by 52.4% in treatment-naïve patients (22.6% vs 75.0%; p< 0.05), though regimen adjustments in pretreated cases showed no benefit (p> 0.05). Notably, Candida species exhibited equivalent virulence (log-rank p> 0.05), and mNGS read counts lacked prognostic value (p> 0.05). Conclusion: mNGS transforms candidemia management by enabling early risk stratification (via SOFA scores and co-infection profiles) and precision therapy initiation. Its capacity to unmask high-risk bacterial synergists and guide time-sensitive interventions supports integration into diagnostic algorithms, particularly for culture-negative cases. Further validation of standardized mNGS protocols is warranted to maximize clinical impact.
- 1 October 2025
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 18, 5263-5275
Open AccessMetagenomic Next-Generation Sequencing Unveils Prognostic Microbial Synergism and Guides Precision Therapy in Candidemia: A Retrospective Cohort Study
Purpose: Candidemia remains a life-threatening infection, compounded by diagnostic delays and limited prognostic tools. While metagenomic next-generation sequencing (mNGS) offers rapid pathogen detection, its prognostic utility and therapeutic impact in candidemia remain unestablished. Patients and Methods: This retrospective cohort study analyzed 97 candidemia patients with positive blood mNGS at West China Hospital (2020– 2024). Multivariable logistic regression and survival analyses identified mortality predictors, while therapeutic impacts were assessed through antifungal regimen modifications. Results: The 28-day mortality was 44.3% (43/97). Blood mNGS outperformed cultures in species identification (5 vs 4 species) and co-infection detection. Bacterial co-detections (HR=2.00, 95% CI:1.15– 3.48; p< 0.05) doubled mortality risk. SOFA score was the strongest mortality predictor (adjusted OR=1.29 per point; p< 0.001). mNGS-guided antifungal initiation reduced mortality by 52.4% in treatment-naïve patients (22.6% vs 75.0%; p< 0.05), though regimen adjustments in pretreated cases showed no benefit (p> 0.05). Notably, Candida species exhibited equivalent virulence (log-rank p> 0.05), and mNGS read counts lacked prognostic value (p> 0.05). Conclusion: mNGS transforms candidemia management by enabling early risk stratification (via SOFA scores and co-infection profiles) and precision therapy initiation. Its capacity to unmask high-risk bacterial synergists and guide time-sensitive interventions supports integration into diagnostic algorithms, particularly for culture-negative cases. Further validation of standardized mNGS protocols is warranted to maximize clinical impact.
- Open Access
- 1 October 2025
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 25 (1) , 1-14
Machine learning model for differentiating Pneumocystis jirovecii pneumonia from colonization and analyzing mortality risk in non-HIV patients using BALF metagenomic sequencing
To identify predictors and risk factors for Pneumocystis jirovecii pneumonia (PJP) in non-HIV immunocompromised patients. Retrospective analysis of 301 non-HIV patients with P. jirovecii in bronchoalveolar lavage fluid (BALF) using metagenomic next-generation sequencing (mNGS) identified PJP (n = 161) and P. jirovecii colonization (PJC, n = 140) groups, evaluated XGBoost for prediction, applied SHAP for insights, and assessed 28-day mortality risks. We assessed five machine learning algorithms, selecting XGBoost as the final predictive model, and applied SHapley Additive exPlanations (SHAP) analysis for interpretability. We assessed 28-day mortality risks. and performed subgroup survival analyses. The XGBoost model achieved an area under the curve (AUC) of 0.9000 in distinguishing PJP from PJC. Key predictors included serum (1–3)-β-D-glucan (BDG) levels, log-transformed reads for P. jirovecii, CD4+ T cell count, and respiratory support. Significant risk factors for 28-day mortality in PJP patients included the use of decreased PaO2/FiO2 ratios (final OR: 0.98, P < 0.001), lower platelet counts (final OR: 0.98, P = 0.057), lower CD3+ (final OR: 0.99, P = 0.034), as was a lower CD4+ T cell count (final OR: 0.98, P = 0.023). Patients with immune-mediated diseases had the worst survival rates. Corticosteroids failed to improve survival, regardless of patients having good or poor oxygenation status. Co-infections, particularly those with multiple pathogens, were associated with the most adverse outcomes. The study underscores mNGS for P. jirovecii detection, XGBoost’s effectiveness in PJP differentiation, and the importance of identifying predictors and mortality risks in clinical management, noting worse outcomes in immune-mediated disease patients and co-infections, with corticosteroids not improving survival.
- 1 October 2025
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 25 (1) , 1-14
Open AccessMachine learning model for differentiating Pneumocystis jirovecii pneumonia from colonization and analyzing mortality risk in non-HIV patients using BALF metagenomic sequencing
To identify predictors and risk factors for Pneumocystis jirovecii pneumonia (PJP) in non-HIV immunocompromised patients. Retrospective analysis of 301 non-HIV patients with P. jirovecii in bronchoalveolar lavage fluid (BALF) using metagenomic next-generation sequencing (mNGS) identified PJP (n = 161) and P. jirovecii colonization (PJC, n = 140) groups, evaluated XGBoost for prediction, applied SHAP for insights, and assessed 28-day mortality risks. We assessed five machine learning algorithms, selecting XGBoost as the final predictive model, and applied SHapley Additive exPlanations (SHAP) analysis for interpretability. We assessed 28-day mortality risks. and performed subgroup survival analyses. The XGBoost model achieved an area under the curve (AUC) of 0.9000 in distinguishing PJP from PJC. Key predictors included serum (1–3)-β-D-glucan (BDG) levels, log-transformed reads for P. jirovecii, CD4+ T cell count, and respiratory support. Significant risk factors for 28-day mortality in PJP patients included the use of decreased PaO2/FiO2 ratios (final OR: 0.98, P < 0.001), lower platelet counts (final OR: 0.98, P = 0.057), lower CD3+ (final OR: 0.99, P = 0.034), as was a lower CD4+ T cell count (final OR: 0.98, P = 0.023). Patients with immune-mediated diseases had the worst survival rates. Corticosteroids failed to improve survival, regardless of patients having good or poor oxygenation status. Co-infections, particularly those with multiple pathogens, were associated with the most adverse outcomes. The study underscores mNGS for P. jirovecii detection, XGBoost’s effectiveness in PJP differentiation, and the importance of identifying predictors and mortality risks in clinical management, noting worse outcomes in immune-mediated disease patients and co-infections, with corticosteroids not improving survival.
- Open Access
- 25 August 2025
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 13, 1634147
Trends in the prevalence of anorexia nervosa among individuals under 45 years in China, 1992–2021: an age-period-cohort analysis
Objective: This study aims to analyze the temporal trends in the incidence and prevalence of anorexia nervosa (AN) in China from 1992 to 2021, focusing on age, period, and cohort effects, in order to provide evidence for the prevention and control of anxiety-related disorders.Methods: Data on the incidence and prevalence of anorexia nervosa in China were obtained from the Global Burden of Disease Study 2021. Joinpoint regression analysis was employed to assess trends over time, while an age-period-cohort (APC) model was used to estimate the net effects of age, period, and cohort variables.Results: From 1992 to 2021, the incidence and prevalence of anorexia nervosa among individuals under 45 years in China showed a general upward trend. The annual percent change (APC) for incidence was 1.29%, and for prevalence was 0.31%, with both rates consistently higher in females than in males. Age effects revealed that the highest incidence and prevalence occurred between ages 10 and 25, followed by a gradual decline. Period effects demonstrated a consistent upward trend across the total population. Cohort analysis indicated an intergenerational increase in the risk of anorexia nervosa.Conclusion: The incidence and prevalence of anorexia nervosa among individuals under 45 years in China have increased steadily from 1992 to 2021. This growing disease burden, with marked age and gender disparities, highlights the urgent need for targeted interventions, especially among adolescents and women.
- 25 August 2025
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 13, 1634147
Open AccessTrends in the prevalence of anorexia nervosa among individuals under 45 years in China, 1992–2021: an age-period-cohort analysis
Objective: This study aims to analyze the temporal trends in the incidence and prevalence of anorexia nervosa (AN) in China from 1992 to 2021, focusing on age, period, and cohort effects, in order to provide evidence for the prevention and control of anxiety-related disorders.Methods: Data on the incidence and prevalence of anorexia nervosa in China were obtained from the Global Burden of Disease Study 2021. Joinpoint regression analysis was employed to assess trends over time, while an age-period-cohort (APC) model was used to estimate the net effects of age, period, and cohort variables.Results: From 1992 to 2021, the incidence and prevalence of anorexia nervosa among individuals under 45 years in China showed a general upward trend. The annual percent change (APC) for incidence was 1.29%, and for prevalence was 0.31%, with both rates consistently higher in females than in males. Age effects revealed that the highest incidence and prevalence occurred between ages 10 and 25, followed by a gradual decline. Period effects demonstrated a consistent upward trend across the total population. Cohort analysis indicated an intergenerational increase in the risk of anorexia nervosa.Conclusion: The incidence and prevalence of anorexia nervosa among individuals under 45 years in China have increased steadily from 1992 to 2021. This growing disease burden, with marked age and gender disparities, highlights the urgent need for targeted interventions, especially among adolescents and women.
- Open Access
- 23 June 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (7) , 367
Targeting DNA Damage Response-Mediated Resistance in Non-Small Cell Lung Cancer: From Mechanistic Insights to Drug Development
Non-small cell lung cancer (NSCLC) remains a major contributor to cancer-related deaths worldwide, with therapeutic resistance presenting a critical clinical hurdle. The DNA damage response (DDR) constitutes a sophisticated cellular framework that detects, signals, and repairs genetic lesions to preserve genomic stability. While the DDR plays a crucial role in determining the efficacy of radiotherapy and chemotherapy, current research primarily focuses on direct DDR inhibitors, often overlooking the broader regulatory networks that modulate DDR activity. This review aims to comprehensively analyze the upstream and downstream pathways governing DDR in NSCLC, highlighting key molecular regulators, signaling interactions, and potential feedback mechanisms contributing to therapy resistance. By identifying novel regulatory targets and clinically relevant biomarkers, we propose innovative therapeutic strategies to enhance treatment efficacy. Our approach seeks to bridge the gap between DDR dysregulation and precision oncology, offering new perspectives on overcoming resistance and improving patient outcomes in NSCLC.
- 23 June 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (7) , 367
Open AccessTargeting DNA Damage Response-Mediated Resistance in Non-Small Cell Lung Cancer: From Mechanistic Insights to Drug Development
Non-small cell lung cancer (NSCLC) remains a major contributor to cancer-related deaths worldwide, with therapeutic resistance presenting a critical clinical hurdle. The DNA damage response (DDR) constitutes a sophisticated cellular framework that detects, signals, and repairs genetic lesions to preserve genomic stability. While the DDR plays a crucial role in determining the efficacy of radiotherapy and chemotherapy, current research primarily focuses on direct DDR inhibitors, often overlooking the broader regulatory networks that modulate DDR activity. This review aims to comprehensively analyze the upstream and downstream pathways governing DDR in NSCLC, highlighting key molecular regulators, signaling interactions, and potential feedback mechanisms contributing to therapy resistance. By identifying novel regulatory targets and clinically relevant biomarkers, we propose innovative therapeutic strategies to enhance treatment efficacy. Our approach seeks to bridge the gap between DDR dysregulation and precision oncology, offering new perspectives on overcoming resistance and improving patient outcomes in NSCLC.
- Open Access
- 13 May 2025
- Published by Springer Nature in Virology Journal
- Vol. 22 (1) , 1-9
Clinical features and risk factors for Epstein-Barr virus-associated encephalitis: a retrospective cohort study
Epstein-Barr virus (EBV) has been gradually recognized as an important pathogen of encephalitis, but our knowledge of EBV-associated encephalitis is still limited. The aim of this study was to describe the clinical features and explore the risk factors for EBV-associated encephalitis in a large cohort of Chinese patients. All patients with confirmed encephalitis in our center from June 2020 to April 2021 were enrolled. Data were extracted from the electronic medical record system and analyzed by Student’s t test, Mann-Whitney U test, chi-square test, and logistic regression analyses. This study included a total of 364 patients diagnosed with encephalitis, among which 86 cases (23.6%) had EBV detected in their cerebrospinal fluid (CSF), and 39 cases were diagnosed with EBV-associated encephalitis. The clinical characteristics of EBV-associated encephalitis differ from those caused by other herpes viruses. Compared to other herpes virus-related encephalitis, patients with EBV encephalitis exhibited significantly higher protein levels (1.310 [0.695, 1.840] vs. 0.710 [0.490, 1.700], p < 0.001), lower glucose levels (3.030 [2.585, 3.640] vs. 3.380 [2.990, 4.030], p < 0.001), and a higher incidence of meningeal involvement on MRI (11 (30.6%) vs. 3 (6.5%), p = 0.010). Additionally, univariate logistic regression analysis revealed that age (OR = 1.015, 95% CI: 1.002–1.029), HIV infection (OR = 4.285, 95% CI: 1.582–11.816), non-tumor immunosuppression (OR = 5.713, 95% CI: 1.588–22.883), and peripheral blood EBV infection (OR = 10.204, 95% CI: 4.231–26.346) were independent risk factors for CNS EBV infection. Compared to other herpes virus-associated encephalitis, EBV encephalitis is characterized by a higher degree of meningeal involvement, elevated CSF protein levels, lower glucose levels, and a reduced T-lymphocyte count in peripheral blood. These characteristics suggest that EBV encephalitis may have a distinct pathophysiology.
- 13 May 2025
- Published by Springer Nature in Virology Journal
- Vol. 22 (1) , 1-9
Open AccessClinical features and risk factors for Epstein-Barr virus-associated encephalitis: a retrospective cohort study
Epstein-Barr virus (EBV) has been gradually recognized as an important pathogen of encephalitis, but our knowledge of EBV-associated encephalitis is still limited. The aim of this study was to describe the clinical features and explore the risk factors for EBV-associated encephalitis in a large cohort of Chinese patients. All patients with confirmed encephalitis in our center from June 2020 to April 2021 were enrolled. Data were extracted from the electronic medical record system and analyzed by Student’s t test, Mann-Whitney U test, chi-square test, and logistic regression analyses. This study included a total of 364 patients diagnosed with encephalitis, among which 86 cases (23.6%) had EBV detected in their cerebrospinal fluid (CSF), and 39 cases were diagnosed with EBV-associated encephalitis. The clinical characteristics of EBV-associated encephalitis differ from those caused by other herpes viruses. Compared to other herpes virus-related encephalitis, patients with EBV encephalitis exhibited significantly higher protein levels (1.310 [0.695, 1.840] vs. 0.710 [0.490, 1.700], p < 0.001), lower glucose levels (3.030 [2.585, 3.640] vs. 3.380 [2.990, 4.030], p < 0.001), and a higher incidence of meningeal involvement on MRI (11 (30.6%) vs. 3 (6.5%), p = 0.010). Additionally, univariate logistic regression analysis revealed that age (OR = 1.015, 95% CI: 1.002–1.029), HIV infection (OR = 4.285, 95% CI: 1.582–11.816), non-tumor immunosuppression (OR = 5.713, 95% CI: 1.588–22.883), and peripheral blood EBV infection (OR = 10.204, 95% CI: 4.231–26.346) were independent risk factors for CNS EBV infection. Compared to other herpes virus-associated encephalitis, EBV encephalitis is characterized by a higher degree of meningeal involvement, elevated CSF protein levels, lower glucose levels, and a reduced T-lymphocyte count in peripheral blood. These characteristics suggest that EBV encephalitis may have a distinct pathophysiology.
- Open Access
- 6 February 2025
- Published by Elsevier in Public Health
- Vol. 240, 174-181
Trend of anxiety disorders in China from 1990 to 2019: An age-period-cohort analysis study
- 6 February 2025
- Published by Elsevier in Public Health
- Vol. 240, 174-181
Open AccessTrend of anxiety disorders in China from 1990 to 2019: An age-period-cohort analysis study
- Open Access
Integrated Whole-Life Cycle Accuracy Valvular Heart Disease Epidemiology Cohort Study (iWAVE): protocol for a prospective cohort study
Introduction Despite the rapid advancements in cardiovascular surgery in China, the prevalence of valvular heart disease (VHD) continues to rise, particularly among the elderly population. In the resource-constrained western regions, the lack of an integrated care management system significantly contributes to the burden of cardiovascular disease. Consequently, a comprehensive cohort data platform that encompasses the entire lifespan of patients with VHD is essential. This prospective cohort study aims to facilitate the examination of risk factor screening, disease progression, diagnostic and treatment strategies, and the long-term functional recovery trajectories of patients following valve surgery. Methods and analysis The Integrated Whole-Life Cycle Accuracy Valvular Heart Disease Epidemiology Cohort Study is a prospective cohort study that plans to enrol approximately 10 000 participants, including both patients with VHD and members of the general population, by 2028. Led by the West China Hospital of Sichuan University, it will be conducted in collaboration with 15 medical consortiums and their affiliated community hospitals. This study seeks to assess the disease trajectory of VHD, as well as the risk factors and protective measures that influence its progression and prognosis. This study will collect and analyse basic demographic information, peripheral blood and tissue samples, long-term functional follow-up data, and patient-reported outcome questionnaires. Additionally, electronic health records will be used to document patients with VHD undergoing surgical interventions, along with lifetime endpoint events for the valve clinical study. Ethics and dissemination The study protocol was approved by the Biomedical Research Ethics Committee of West China Hospital of Sichuan University (No. 20232422). All participants will be required to provide written informed consent. The study findings will be disseminated via publications in peer-reviewed journals and presentations at scientific conferences.
Open AccessIntegrated Whole-Life Cycle Accuracy Valvular Heart Disease Epidemiology Cohort Study (iWAVE): protocol for a prospective cohort study
Introduction Despite the rapid advancements in cardiovascular surgery in China, the prevalence of valvular heart disease (VHD) continues to rise, particularly among the elderly population. In the resource-constrained western regions, the lack of an integrated care management system significantly contributes to the burden of cardiovascular disease. Consequently, a comprehensive cohort data platform that encompasses the entire lifespan of patients with VHD is essential. This prospective cohort study aims to facilitate the examination of risk factor screening, disease progression, diagnostic and treatment strategies, and the long-term functional recovery trajectories of patients following valve surgery. Methods and analysis The Integrated Whole-Life Cycle Accuracy Valvular Heart Disease Epidemiology Cohort Study is a prospective cohort study that plans to enrol approximately 10 000 participants, including both patients with VHD and members of the general population, by 2028. Led by the West China Hospital of Sichuan University, it will be conducted in collaboration with 15 medical consortiums and their affiliated community hospitals. This study seeks to assess the disease trajectory of VHD, as well as the risk factors and protective measures that influence its progression and prognosis. This study will collect and analyse basic demographic information, peripheral blood and tissue samples, long-term functional follow-up data, and patient-reported outcome questionnaires. Additionally, electronic health records will be used to document patients with VHD undergoing surgical interventions, along with lifetime endpoint events for the valve clinical study. Ethics and dissemination The study protocol was approved by the Biomedical Research Ethics Committee of West China Hospital of Sichuan University (No. 20232422). All participants will be required to provide written informed consent. The study findings will be disseminated via publications in peer-reviewed journals and presentations at scientific conferences.